A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company’s portfolio. Novo has chances to rescue the program with its ongoing Artemis and Hermes trials.